The company reports on its financial performance on a quarterly basis starting its financial year on January 01.
Results published on April 30, 2025:
The company reports on its financial performance on a quarterly basis starting its financial year on January 01.
for the Idorsia-led portfolio in 2025, the company expects a continued acceleration of QUVIVIQ with net sales of around CHF 110 million, COGS of around CHF 15 million, SG&A expenses of around CHF 210 million, and R&D expense of around CHF 100 million, leading to non-GAAP operating expenses of around CHF 325 million. This performance would result in an Idorsia-led business non-GAAP operating loss of around CHF 215 million and US-GAAP operating loss of around CHF 260 million. The company expects US-GAAP EBIT for the partnered business of around CHF 135 million – updated to reflect the positive impact of the one-off exclusivity fee paid by an undisclosed party in Q4 2024 but recognized in Q1 2025 – and mainly driven by the amended deal with Viatris. This would result in a US-GAAP loss for the global business of around CHF 125 million. All amounts exclude unforeseen events and potential revenue related to additional business development activities.
“The updated agreement with Viatris, and the convertible debt restructuring, together with the new money facility agreed with our bondholders, has significantly changed the financial situation of Idorsia. That said, there are still several steps to implement in order to realize what was agreed. The restructuring of the bonds is moving forward with the first step approved by the court, allowing us to proceed to the next bondholder meetings. We are also making progress with putting the new money facility in place. The excellent uplift with QUVIVIQ in Europe and the tight cost-control means we are well on track with our financial performance targets.”
(April 2025)
Arno Groenewoud
Chief Financial Officer
First Quarter | ||||
in CHF millions, except EPS (CHF) and number of shares (millions) |
2025 |
2024 |
||
Net revenues |
59 |
10 |
||
Operating expenses |
5 |
20 |
||
Operating income (loss) |
67 |
31 |
||
Net income (loss) |
63 |
30 |
||
Basic EPS |
0.33 |
0.17 |
||
Basic weighted average number of shares |
188.9 |
179.1 |
||
Diluted EPS |
0.23 |
0.13 |
||
Diluted weighted average number of shares |
270.8 |
233.3 |
Net revenue of CHF 59 m in Q1 2025 resulted from QUVIVIQ product sales (CHF 25 m), product sales to partners (CHF 1 m), and contract revenues (CHF 32 m), comprising a one-off exclusivity fee of CHF 32 m paid by an undisclosed party in relation to a potential aprocitentan deal, and non-cash revenue related to the R-Bridge royalty monetization agreement of CHF 1 m. This compares to net revenue of CHF 10 m in Q1 2024 from QUVIVIQ product sales.
US GAAP operating expenses of CHF 5 m (income) in Q1 2025 and CHF 20 m (income) in Q1 2024 were impacted by a one-off gain of CHF 90 m (Viatris deal amendment) in 2025 and CHF 125 m (Viatris deal) in 2024, respectively. Excluding these one-off gains, US GAAP operating expenses at Q1 2025 decreased by CHF 20 m, mainly driven by R&D expenses of CHF 27 m decreasing by CHF 6 m compared to Q1 2024 (CHF 33 m), and SG&A expenses of CHF 54 m decreasing by CHF 14 m compared to Q1 2024 (CHF 68 m).
US GAAP net income in Q1 2025 of CHF 63 m (CHF 27 m net loss excluding Viatris deal amendment) and CHF 30 m in Q1 2024 (CHF 95 m net loss excluding Viatris deal). Excluding these one-offs, the reduced net loss in Q1 2025 was primarily due to lower operating expenses from cost savings through the effective restructuring efforts announced in November 2024 and higher revenue.
The US GAAP net income resulted in a basic net income per share of CHF 0.33 (diluted net income per share of CHF 0.23) in Q1 2025, compared to a basic net income per share of CHF 0.17 (diluted net income per share of CHF 0.13) in Q1 2024.
First Quarter | ||||
in CHF millions, except EPS (CHF) and number of shares (millions) |
2025 |
2024 |
||
Net revenues |
58 |
10 |
||
Operating expenses |
(78) |
(96) |
||
Operating income (loss) |
(17) |
(85) |
||
Net income (loss) |
(25) |
(86) |
||
Basic EPS |
(0.13) |
(0.48) |
||
Basic weighted average number of shares |
188.9 |
179.1 |
||
Diluted EPS |
(0.13) |
(0.48) |
||
Diluted weighted average number of shares |
188.9 |
179.1 |
Non-GAAP net loss in Q1 2025 amounted to CHF 25 m; the difference versus US GAAP net income was mainly driven by the one-off gain from the amendment of the Viatris Deal (CHF 90 m).
The non-GAAP net loss resulted in a net loss per share of CHF 0.13 (basic and diluted) in Q1 2025, compared to a net loss per share of CHF 0.48 (basic and diluted) in Q1 2024.
At the end of the first quarter of 2025, Idorsia’s liquidity amounted to CHF 51 million.
Type of debt |
Mar 31, 2025 |
Dec 31, 2024 |
|
Convertible loan |
335 |
335 |
|
Convertible bond |
797 |
797 |
|
Other financial debt |
190 |
189 |
|
Total indebtedness | CHF 1,322 million |
CHF 1,321 million |
* rounding difference may occur
Here we provide a 5-year archive of our financial reports and related reporting documentation.
Results published on April 30, 2025:
Results published on March 4, 2025:
Results published on October 29, 2024.
Results published on July 25, 2024.
Results published on May 21, 2024:
Results published on May 21, 2024:
Results published on October 24, 2023:
Results published on July 25, 2023:
Results published on April 25, 2023:
Results published on February 7, 2023:
Results published on October 25, 2022:
Results published on July 26, 2022:
Results published on April 26, 2022:
Results published on February 8, 2022:
Results published on October 26, 2021:
Results published on July 27, 2021:
Results published on April 22, 2021:
Results published on February 4, 2021:
Results published on October 27, 2020:
Results published on July 23, 2020:
Results published on April 23, 2020:
Results published on February 6, 2020:
Results published on October 22, 2019:
Results published on July 23, 2019:
Results published on April 18, 2019: